Sivem Pharmaceuticals ULC — licence 101965, currently licensed, last inspection rating C (2025-02-04).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02490986 | ACH-IMATINIB | ACCORD HEALTHCARE INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02490994 | ACH-IMATINIB | ACCORD HEALTHCARE INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02355337 | APO-IMATINIB | APOTEX INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02355345 | APO-IMATINIB | APOTEX INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02253275 | GLEEVEC | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02253283 | GLEEVEC | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02504618 | IMATINIB | SANIS HEALTH INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02504596 | IMATINIB | SANIS HEALTH INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02521210 | IMATINIB | SIVEM PHARMACEUTICALS ULC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02492334 | MINT-IMATINIB | MINT PHARMACEUTICALS INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02492342 | MINT-IMATINIB | MINT PHARMACEUTICALS INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02397285 | NAT-IMATINIB | NATCO PHARMA (CANADA) INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02397293 | NAT-IMATINIB | NATCO PHARMA (CANADA) INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02428318 | TARO-IMATINIB | SUN PHARMA CANADA INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Approved |
| 02428326 | TARO-IMATINIB | SUN PHARMA CANADA INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Approved |
| 02399806 | TEVA-IMATINIB | TEVA CANADA LIMITED | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Marketed |
| 02399814 | TEVA-IMATINIB | TEVA CANADA LIMITED | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Marketed |
| 02244725 | GLEEVEC | NOVARTIS PHARMACEUTICALS CANADA INC | Capsule | IMATINIB (IMATINIB MESYLATE) 100 MG | Cancelled Post Market |
| 02495074 | JAMP IMATINIB | JAMP PHARMA CORPORATION | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Dormant |
| 02495066 | JAMP IMATINIB | JAMP PHARMA CORPORATION | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Dormant |
| 02424495 | MYLAN-IMATINIB | MYLAN PHARMACEUTICALS ULC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Cancelled Pre Market |
| 02424509 | MYLAN-IMATINIB | MYLAN PHARMACEUTICALS ULC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Cancelled Pre Market |
| 02431122 | PMS-IMATINIB | PHARMASCIENCE INC | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Dormant |
| 02431114 | PMS-IMATINIB | PHARMASCIENCE INC | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Dormant |
| 02515547 | SANDOZ IMATINIB | SANDOZ CANADA INCORPORATED | Tablet | IMATINIB (IMATINIB MESYLATE) 100 MG | Cancelled Pre Market |
| 02515555 | SANDOZ IMATINIB | SANDOZ CANADA INCORPORATED | Tablet | IMATINIB (IMATINIB MESYLATE) 400 MG | Cancelled Pre Market |